At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
nab-Sirolimusdrug
Likely dose
nab-Sirolimus 100 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (Nab-sirolimus) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
In Brief
A Phase 2 clinical trial evaluating nab-Sirolimus for Malignant PEComa. Completed, enrolled 34 participants across 9 sites.
Detailed Summary
A phase 2 multi-center investigation of efficacy of nab-sirolimus (formerly known as ABI-009 or nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant PEComa
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartOct 2015
Primary CompletionNov 2021
Study CompletionApr 2022
TodayJul 2026
First PostedJul 10, 2015
Enrollment StartOct 1, 2015
Primary CompletionNov 1, 2021
Study CompletionApr 1, 2022
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 11.0 years ago
Interventions
nab-Sirolimusdrug
Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.